Comparable peri-transplant mortality and incidence of febrile neutropenia after high-dose melphalan and autologous stem cell transplantation in patients with plasma cell dyscrasias treated as outpatient versus inpatient

Br J Haematol. 2025 Oct;207(4):1679-1683. doi: 10.1111/bjh.70104. Epub 2025 Sep 2.

Ana Maria Avila Rodriguez^{1

2}, Xiao Hu^{3

4}, Cindy Varga^{3

5}, Raymond Comenzo³, Shayna Sarosiek^{1

6}, J Mark Sloan¹, Vaishali Sanchorawala¹, Gheorghe Doros⁷, Karen Quillen^{1

8}

¹ Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
² Division of Hematology/Oncology, University of Illinois at Chicago, Chicago, Illinois, USA.
³ Division of Hematology-Oncology, Tufts Medical Center, Boston, Massachusetts, USA.
⁴ MaineHealth Cancer Care, Portland, Maine, USA.
⁵ Atrium Health Levine Cancer Institute, Charlotte, North Carolina, USA.
⁶ Dana Farber Cancer Institute, Bing Center for Waldenstrom's Macroglobulinemia, Boston, Massachusetts, USA.
⁷ Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA.
⁸ Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.

No abstract available

Keywords: AL amyloidosis; multiple myeloma; stem cell transplantation.

Grants and funding